Seprafilm Adhesion Barrier
Adhesions are a very common complication of surgery
but there is a way to reduce their incidence and severity
Key facts from a selection of clinical studies
In a prospective, multicenter, randomized, controlled, blinded study of patients receiving Seprafilm during intestinal resection, Seprafilm reduced reoperation required for Small Bowel Obstruction by 47% relative to untreated controls. 4
In one study patients who received Seprafilm were 8.5 times more likely to be adhesion free compared to patients who did not receive an adhesion barrier. It also reduced the incidence of dense adhesions by 74% compared with untreated patients. 5
In a study of women receiving Seprafilm at their first C-Section, up to 93%* of the patients were adhesion free, resulting in decreased procedure and delivery times at repeat C-Sections. 6
In a study of patients having their ovaries, fallopian tubes, and uterus removed, patients who received Seprafilm had nearly 70% fewer adhesions than patients who did not receive an adhesion barrier .7
Seprafilm is a sterile, bioresorbable, translucent adhesion barrier composed of 2 polysaccharides: sodium hyaluronate (HA) and carboxymethylcellulose (CMC) that have been chemically modified. HA is a naturally occurring polysaccharide expressed throughout the human body. CMC, also a polysaccharide, is a derivative of cellulose. Both are common components in pharmaceuticals, foods, and cosmetics. The properties of these components render Seprafilm hydrophilic—so it does not require suturing and stays where it is applied until resorbed.
When applied as directed, Seprafilm Adhesion Barrier can be expected to reduce the incidence, extent, and severity of adhesions within the abdominopelvic cavity. Seprafilm becomes a gel within 24 to 48 hours after placement. It is slowly resorbed within a week and is excreted from the body in less than 28 days.
1. Menzies D, Ellis H. Intestinal obstruction from adhesions—how big is the problem? Ann R Coll Surg Engl. 1990;72(1):60-63.
2. Scovill WA. Small bowel obstruction. In: Cameron JL, ed. Current Therapy in Surgery. 5th ed: St Louis, MO: Mosby; 1995:100-104.
3. Peterson (1970) Laparoscopy of the infertile patient obstet gynecol. 6. Phillippov (1998) Estimation of the prevalence & causes of infertility bull world health organ
4. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2005;49(1):1-11
5. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
6. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of Seprafilm as an adhesion prevention barrier in cesarean sections. Obstet Gynecol Treatment. 2005;91(5):557-561.
7. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005;99(2):301-308.
Seprafilm® is proven to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy
Seprafilm® has been used in more than 4 Million patients worldwide since its introduction in 1996 making it the most widely used adhesion barrier.
Seprafilm® has been studied in more than 4000 patients, and featured in more than 40 studies.
For more information on Adhesions - their formation, impact and prevention visit the Elsevier Postoperative Adhesions Awareness website
Case where Seprafilm used previously
Case without prior Seprafilm